Effects of pre-existing heart failure with preserved ejection fraction (HFpEF) on the outcomes of patients with COVID-19: a systematic review
24 May 2022 (10:28 - 10:40)
Organised by:
Slides
About the speaker
AstraZeneca BioPharmaceuticals, Gaithersburg (United States of America)
4 More presentations in this session
Miss I. Vasconcelos (Porto, PT)
Doctor A. Lena (Berlin, DE)
Miss J. Santos Peixoto Gomes (Porto, PT)
Associate Professor R. Puri (Cleveland, US)
Access the full session
The Event
Heart Failure 2022
24 May 2022
10:28 CET
